J. Scott Wolchko net worth and biography

J. Wolchko Biography and Net Worth

CEO of Fate Therapeutics

Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

What is J. Scott Wolchko's net worth?: The estimated net worth of J. Scott Wolchko is at least $697,946.24 as of January 9th, 2024. Mr. Wolchko owns 371,248 shares of Fate Therapeutics stock worth more than $697,946 as of December 18th. This net worth approximation does not reflect any other investments that Mr. Wolchko may own. Additionally, Mr. Wolchko receives an annual salary of $920,400.00 as CEO at Fate Therapeutics. Learn More about J. Scott Wolchko's net worth.
How old is J. Scott Wolchko?: Mr. Wolchko is currently 54 years old. There are 3 older executives and no younger executives at Fate Therapeutics. Learn More on J. Scott Wolchko's age.
What is J. Scott Wolchko's salary?: As the CEO of Fate Therapeutics, Inc., Mr. Wolchko earns $920,400.00 per year. Learn More on J. Scott Wolchko's salary.
How do I contact J. Scott Wolchko?: The corporate mailing address for Mr. Wolchko and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on J. Scott Wolchko's contact information.
Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?: J. Scott Wolchko has not been actively trading shares of Fate Therapeutics in the last ninety days. Most recently, J Scott Wolchko sold 14,391 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a transaction totalling $62,888.67. Following the completion of the sale, the chief executive officer now directly owns 371,248 shares of the company's stock, valued at $1,622,353.76. Learn More on J. Scott Wolchko's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 8/6/2024.

J. Scott Wolchko Insider Trading History at Fate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2024	Sell	14,391	$4.37	$62,888.67	371,248
1/10/2023	Sell	45,907	$5.24	$240,552.68	385,639
7/21/2022	Sell	30,000	$32.88	$986,400.00	431,546
4/21/2022	Sell	30,000	$35.00	$1,050,000.00	431,546
1/20/2022	Sell	30,000	$40.21	$1,206,300.00
1/10/2022	Sell	34,156	$46.86	$1,600,550.16
11/18/2021	Sell	20,000	$54.27	$1,085,400.00
10/21/2021	Sell	30,000	$60.22	$1,806,600.00
8/19/2021	Sell	20,000	$88.01	$1,760,200.00
7/22/2021	Sell	30,000	$86.05	$2,581,500.00
4/23/2021	Sell	30,000	$85.24	$2,557,200.00	423,793
1/21/2021	Sell	30,000	$103.05	$3,091,500.00	393,793
1/11/2021	Sell	69,407	$116.33	$8,074,116.31	393,065
1/8/2021	Sell	60,820	$117.10	$7,122,022.00	393,065
11/13/2020	Sell	60,000	$51.87	$3,112,200.00
1/30/2020	Sell	25,000	$25.45	$636,250.00	444,969
12/20/2019	Sell	25,000	$20.17	$504,250.00	378,969
10/15/2019	Sell	21,017	$14.44	$303,485.48
5/16/2019	Sell	14,335	$19.37	$277,668.95	389,216
4/17/2019	Sell	8,541	$16.17	$138,107.97	375,973
3/21/2019	Sell	20,000	$17.61	$352,200.00
4/1/2014	Sell	20,000	$9.64	$192,800.00

J. Scott Wolchko Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.88

$1.85

$2.02

50 Day Range

MA: $2.63

$1.83

$3.23

2 Week Range

Now: $1.88

$1.82

$8.83

Volume

2,811,176 shs

Average Volume

2,407,703 shs

Market Capitalization

$214.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.

J. Wolchko Biography and Net Worth

What is J. Scott Wolchko's net worth?

How old is J. Scott Wolchko?

What is J. Scott Wolchko's salary?

How do I contact J. Scott Wolchko?

Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?

Who are Fate Therapeutics' active insiders?

Are insiders buying or selling shares of Fate Therapeutics?